CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine.
In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.